Advanced Radiopharmaceutical Therapy for Bone Metastatic Prostate Cancer: Xofigo® (Radium Ra 223 Dichloride)

Targeted Treatment for Bone Metastases

United Theranostics offers advanced care for patients with metastatic prostate cancer that has spread to the bones. Xofigo® (radium Ra 223 dichloride) is a targeted radiopharmaceutical therapy designed to deliver radiation directly to bone metastases, improving outcomes and quality of life.

Request An Appointment

Why Choose Xofigo® Therapy?

Bone-Targeted Radiation: Selectively homes to areas of bone metastasis for precise treatment.
Survival Benefit: Shown to extend survival and delay bone-related complications in eligible patients.
Symptom Relief: Reduces bone pain and risk of skeletal events.
Outpatient Convenience: Quick, simple injections performed in an outpatient setting.

How the Therapy Works

Eligibility Assessment: Imaging and evaluation confirm bone-only metastases from prostate cancer.
Treatment Administration: Xofigo® is given as an intravenous injection, typically every four weeks for six cycles.
Targeted Action: Delivers alpha radiation to bone metastases, destroying cancer cells while sparing healthy tissue.
Ongoing Monitoring: Blood tests and follow-up visits ensure safety and effectiveness.

Who Can Benefit?

Men with metastatic castration-resistant prostate cancer (mCRPC) limited to the bones.
Patients experiencing bone pain or at risk for bone-related complications.

Frequently Asked Questions (FAQ)

B
C

What is Xofigo® (radium Ra 223 dichloride)?

Xofigo® is a radiopharmaceutical therapy that delivers targeted alpha radiation to bone metastases from prostate cancer, helping control cancer growth and reduce symptoms.
B
C

How is Xofigo® administered?

It’s given as a series of intravenous injections, typically once every four weeks for a total of six treatments.
B
C

Who is eligible for Xofigo® therapy?

Eligibility is based on having metastatic prostate cancer that has spread only to the bones (not to other organs). Imaging and lab work confirm suitability.
B
C

What are the common side effects?

Side effects may include nausea, diarrhea, low blood counts (anemia, low platelets, low white cells), and mild injection site reactions. Our team monitors you closely and provides support for any side effects.
B
C

Will I be radioactive after treatment?

The radioactivity is primarily confined to the bones and is rapidly cleared from the body. Risk to others is minimal, but our team will review any necessary safety precautions.
B
C

How soon can I start treatment?

There is no waiting period after your initial consultation and eligibility assessment—treatment can begin promptly.
B
C

Is Xofigo® covered by insurance?

United Theranostics assists with insurance verification and can help identify financial assistance programs for eligible patients.
B
C

What follow-up care is required?

Regular blood tests and follow-up visits are scheduled to monitor your health and response to therapy.
B
C

Where can I receive treatment?

Xofigo® therapy is available at United Theranostics facilities in New York, New Jersey, Pennsylvania, Maryland, and New Mexico.

United Theranostics: Leaders in Precision Oncology

Expertise: Experienced in advanced molecular imaging and targeted radiopharmaceutical therapies.
Personalized Support: Comprehensive care from consultation through follow-up.
Accessible Locations: Multiple facilities across five states.

Take the Next Step

If you or a loved one has metastatic prostate cancer with bone involvement, contact United Theranostics for more information or to schedule a personalized consultation.

Appointments & Consultations:

 

Contact Us